Oonagh Sheehy

Belfast, NIR, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Belfast, NIR, GB 

Overview

Oonagh Sheehy practices practicing medicine in Belfast, United Kingdom.

Her clinical expertise encompasses Rosai-Dorfman Disease, Follicular Lymphoma, Small Lymphocytic Lymphoma (SLL), and Chronic Lymphocytic Leukemia (CLL).

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Belfast, NIR, United Kingdom
Other Locations
Chippenham, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 1 Less Clinical Trial

8 Total Publications

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: June 16, 2025

Frequently Asked Questions about Oonagh Sheehy

Is Oonagh Sheehy a top-rated expert for Rosai-Dorfman Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Oonagh Sheehy is classified as an Experienced expert for Rosai-Dorfman Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Oonagh Sheehy participate in research or clinical trials?

Yes. Oonagh Sheehy has published 8 articles and abstracts on conditions like Rosai-Dorfman Disease. You can view a list of Oonagh Sheehy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sheehy's expertise for a condition
ConditionClose
        View All 9 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile